Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: The potential of combination strategies

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 1, 2014, Pages 38-48

  Boer, Jennifer C ^a   Walenkamp, Annemiek M E ^a   Dunnen, Wilfred F A den ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Bone marrow derived cells; GBM; Resistance; VEGF

Indexed keywords

ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR4; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BONE MARROW CELL; BRAIN PERICYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL ACTIVITY; CELL FUNCTION; CELL MIGRATION; DRUG RESPONSE; ENDOTHELIAL PROGENITOR CELL; GLIOBLASTOMA; HUMAN; MONOCYTE; NONHUMAN; RADIATION RESPONSE; REVIEW; TREATMENT OUTCOME; TUMOR VASCULARIZATION; ANIMAL; BONE MARROW; DRUG RESISTANCE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW CELLS; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84906939420     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.05.001     Document Type: Review

References (109)

1. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-466.
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
3. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740.
4. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30):4722-4729.
5. Cohen M.H., Shen Y.L., Keegan P., Pazdur R. FDA drug approval summary: Bevacizumab (avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14(11):1131-1138.
6. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8(8):592-603.
7. Iwamoto F.M., Abrey L.E., Beal K., et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73(15):1200-1206.
8. Du R., Lu K.V., Petritsch C., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13(3):206-220.
9. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2(4):306-314.
10. Shojaei F., Wu X., Malik A.K., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007, 25(8):911-920.
11. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284(5422):1994-1998.
12. Kurz H., Burri P.H., Djonov V.G. Angiogenesis and vascular remodeling by intussusception: from form to function. News Physiol Sci 2003, 18:65-70.
13. Djonov V., Baum O., Burri P.H. Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res 2003, 314(1):107-117.
14. Ricci-Vitiani L., Pallini R., Biffoni M., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468(7325):824-828.
15. El Hallani S., Boisselier B., Peglion F., et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010, 133(Pt 4):973-982.
16. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427(6976):695.
17. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359(6398):843-845.
18. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131(3):463-475.
19. Lyden D., Hattori K., Dias S., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7(11):1194-1201.
20. Aghi M., Cohen K.S., Klein R.J., Scadden D.T., Chiocca E.A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006, 66(18):9054-9064.
21. Calvani M., Rapisarda A., Uranchimeg B., Shoemaker R.H., Melillo G. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 2006, 107(7):2705-2712.
22. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10(8):858-864.
23. Namiki A., Brogi E., Kearney M., et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 1995, 270(52):31189-31195.
24. Simon M.P., Tournaire R., Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and ets-1. J Cell Physiol 2008, 217(3):809-818.
25. Nilsson I., Shibuya M., Wennstrom S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 2004, 299(2):476-485.
26. Guo P., Hu B., Gu W., et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003, 162(4):1083-1093.
27. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7(9):870-879.
28. Zhang Y., Patel S., Abdelouahab H., et al. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis 2012, 3:e396.
29. Hall A.P. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol Pathol 2006, 34(6):763-775.
30. Rajantie I., Ilmonen M., Alminaite A., Ozerdem U., Alitalo K., Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004, 104(7):2084-2086.
31. Wagemakers M., Sie M., Hoving E.W., Molema G., de Bont E.S., den Dunnen W.F. Tumor vessel biology in pediatric intracranial ependymoma. J Neurosurg Pediatr 2010, 5(4):335-341.
32. Hamdan R., Zhou Z., Kleinerman E.S. SDF-1alpha induces PDGF-B expression and the differentiation of bone marrow cells into pericytes. Mol Cancer Res 2011, 9(11):1462-1470.
33. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275(5302):964-967.
34. Peters B.A., Diaz L.A., Polyak K., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005, 11(3):261-262.
35. Machein M.R., Renninger S., de Lima-Hahn E., Plate K.H. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 2003, 13(4):582-597.
36. Moore X.L., Lu J., Sun L., Zhu C.J., Tan P., Wong M.C. Endothelial progenitor cells' "homing" specificity to brain tumors. Gene Ther 2004, 11(10):811-818.
37. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13(3):193-205.
38. Prokopi M., Pula G., Mayr U., et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 2009, 114(3):723-732.
39. Yoder M.C. Human endothelial progenitor cells. Cold Spring Harb Perspect Med 2012, 2(7):a006692.
40. Richardson M.R., Yoder M.C. Endothelial progenitor cells: quo vadis?. J Mol Cell Cardiol 2011, 50(2):266-272.
41. Basile D.P., Yoder M.C. Circulating and tissue resident endothelial progenitor cells. J Cell Physiol 2014, 229(1):10-16.
42. Strunk D. Endothelial progenitor cells: quod erat demonstrandum?. Curr Pharm Des 2011, 17(30):3245-3251.
43. Case J., Mead L.E., Bessler W.K., et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007, 35(7):1109-1118.
44. Estes M.L., Mund J.A., Mead L.E., et al. Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential. Cytometry A 2010, 77(9):831-839.
45. Medina R.J., O'Neill C.L., Sweeney M., et al. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics 2010, 3:18-8794.
46. Tura O., Skinner E.M., Barclay G.R., et al. Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow. Stem Cells 2013, 31(2):338-348.
47. Jiga J., Hoinoiu B., Stoichitoiu T., et al. Induction of therapeutic neoangiogenesis using in vitro-generated endothelial colony-forming cells: an autologous transplantation model in rat. J Surg Res 2013, 181(2):359-368.
48. Bieback K., Vinci M., Elvers-Hornung S., et al. Recruitment of human cord blood-derived endothelial colony-forming cells to sites of tumor angiogenesis. Cytotherapy 2013, 15(6):726-739.
49. Zhang S.H., Xiang P., Wang H.Y., Lu Y.Y., Luo Y.L., Jiang H. The characteristics of bone marrow-derived endothelial progenitor cells and their effect on glioma. Cancer Cell Int 2012, 12(1):32-2867.
50. Guo K.T., Juerchott K., Fu P., et al. Isolation and characterization of bone marrow-derived progenitor cells from malignant gliomas. Anticancer Res 2012, 32(11):4971-4982.
51. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23(11):549-555.
52. Nishie A., Ono M., Shono T., et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 1999, 5(5):1107-1113.
53. Mantovani A., Allavena P., Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression. Eur J Cancer 2004, 40(11):1660-1667.
54. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4(1):71-78.
55. Heusinkveld M., van der Burg S.H. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011, 9. 216-5876-9-216.
56. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009, 86(5):1065-1073.
57. Song N., Huang Y., Shi H., et al. Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res 2009, 69(15):6057-6064.
58. Heissig B., Hattori K., Dias S., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109(5):625-637.
59. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259.
60. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5):740-745.
61. Ballman K.V., Buckner J.C., Brown P.D., et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007, 9(1):29-38.
62. Wick W., Weller M., van den Bent M., Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010, 28(12):e188-e189. author reply e190-2.
63. Tanaka S., Louis D.N., Curry W.T., Batchelor T.T., Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat Rev Clin Oncol 2013, 10(1):14-26.
64. De Witt Hamer P.C. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 2010, 12(3):304-316.
65. Batchelor T.T., Mulholland P., Neyns B., et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013, 31(26):3212-3218.
66. Lee E.Q., Kuhn J., Lamborn K.R., et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American brain tumor consortium study 05-02. Neuro Oncol. 2012, 14(12):1511-1518.
67. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28(11):1963-1972.
68. Lai A., Tran A., Nghiemphu P.L., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011, 29(2):142-148.
69. Narayana A., Gruber D., Kunnakkat S., et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 2012, 116(2):341-345.
70. Gilbert M.R., Dignam J.J., Armstrong T.S., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370(8):699-708.
71. Chinot O.L., Wick W., Mason W., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014, 370(8):709-722.
72. Gilbert M.R., Dignam J., Won M., et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (bev) in patients (pts) with newly diagnosed glioblastoma (GBM). ASCO Meeting Abstr 2013, 31(18_suppl):1.
73. Wick W., Cloughesy T.F., Nishikawa R., et al. Tumor response based on adapted macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). ASCO Meeting Abstr 2013, 31(15_suppl):2002.
74. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012, 320(2):130-137.
75. Inai T., Mancuso M., Hashizume H., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165(1):35-52.
76. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
77. Goel S., Wong A.H., Jain R.K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012, 2(3):a006486.
78. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13(13):3942-3950.
79. Piao Y., Liang J., Holmes L., et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 2012, 14(11):1379-1392.
80. Shaked Y., Ciarrocchi A., Franco M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313(5794):1785-1787.
81. De Palma M., Venneri M.A., Galli R., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8(3):211-226.
82. Schioppa T., Uranchimeg B., Saccani A., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003, 198(9):1391-1402.
83. Hiratsuka S., Duda D.G., Huang Y., et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (gr-1)-positive cells. Proc Nat Acad Sci USA 2011, 108(1):302-307.
84. Venneri M.A., De Palma M., Ponzoni M., et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007, 109(12):5276-5285.
85. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277(5322):55-60.
86. Scharpfenecker M., Fiedler U., Reiss Y., Augustin H.G. The tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005, 118(Pt 4):771-780.
87. Murdoch C., Tazzyman S., Webster S., Lewis C.E. Expression of tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007, 178(11):7405-7411.
88. Coffelt S.B., Tal A.O., Scholz A., et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010, 70(13):5270-5280.
89. Huang J., Bae J.O., Tsai J.P., et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol 2009, 34(1):79-87.
90. Daly C., Eichten A., Castanaro C., et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013, 73(1):108-118.
91. Coxon A., Bready J., Min H., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: Implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010, 9(10):2641-2651.
92. Falcon B.L., Hashizume H., Koumoutsakos P., et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009, 175(5):2159-2170.
93. Bach F., Uddin F.J., Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007, 33(1):7-15.
94. Machein M.R., Knedla A., Knoth R., Wagner S., Neuschl E., Plate K.H. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 2004, 165(5):1557-1570.
95. Shim W.S., Teh M., Bapna A., et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res 2002, 279(2):299-309.
96. Ahmad S.A., Liu W., Jung Y.D., et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001, 61(4):1255-1259.
97. Lamagna C., Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. J Leukoc Biol 2006, 80(4):677-681.
98. Li B., Sharpe E.E., Maupin A.B., et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006, 20(9):1495-1497.
99. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999, 85(3):221-228.
100. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295.
101. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23(31):8136-8139.
102. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
103. Van de Veire S., Stalmans I., Heindryckx F., et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141(1):178-190.
104. Bais C., Wu X., Yao J., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141(1):166-177.
105. Wyler von Ballmoos M., Yang Z., Volzmann J., Baumgartner I., Kalka C., Di Santo S. Endothelial progenitor cells induce a phenotype shift in differentiated endothelial cells towards PDGF/PDGFRbeta axis-mediated angiogenesis. PLoS One 2010, 5(11):e14107.
106. Guo S., Yu L., Cheng Y., et al. PDGFRbeta triggered by bFGF promotes the proliferation and migration of endothelial progenitor cells via p-ERK signalling. Cell Biol Int 2012, 36(10):945-950.
107. Brennan C., Momota H., Hambardzumyan D., et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009, 4(11):e7752.
108. Hermanson M., Funa K., Hartman M., et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992, 52(11):3213-3219.
109. Jo N., Mailhos C., Ju M., et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006, 168(6):2036-2053.